Davide Capodanno: Independent Investigators Lead the First Head to Head DOAC Comparison
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in NEJM:
“Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs – something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests.
This was driven by independent investigators.
The results somewhat support the idea of apixaban being the ‘safer’ DOAC.
That said, the list of study limitations is long, and for me, labeling something as ‘safe’ is not enough — after all, even placebo is ‘safe’ when it comes to bleeding.”
Ali Kamiar, Graduate Student Research Assistant Graduate Student, Research Assistant at University of Miami, Miller School of Medicine, reposted Davide Capodanno’s post on LinkedIn.
“Valuable independent evidence comparing major DOACs. Highlights the importance of critically evaluating both safety endpoints and study limitations when translating data into clinical practice.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow